Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 13Kidney Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1

Interventions

Temozolomide 41Radiotherapy 19Radiation 12Nivolumab 10pembrolizumab 8Magnetic Resonance Spectroscopy 8Bevacizumab 7Specimen Handling 6poly ICLC 4atezolizumab 4Lomustine 4Ipilimumab 4Surgical Procedures, Operative 3Photons 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3veliparib 2sargramostim 2rocakinogene sifuplasmid 2olaparib 2niraparib 2Transurethral Resection of Bladder 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2OKN 007 2Mycophenolic Acid 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Glioblastoma × belzutifan × Clear all
NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡